Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference
暂无分享,去创建一个
E. Winer | J. Forbes | J. Robertson | H. Sasano | T. Inamoto | A. Yamauchi | J. Benson | M. Toi | G. Minckwitz | V. Klimberg | M. Mitsumori | Michihide | Mitsumori
[1] M. Sabel. Surgical considerations in early-stage breast cancer: lessons learned and future directions. , 2011, Seminars in radiation oncology.
[2] M. Morrow. Trends in the Surgical Treatment of Breast Cancer , 2010, The breast journal.
[3] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[4] A. Luini,et al. Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer? , 2009, Annals of Surgical Oncology.
[5] A. Luini,et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Rademaker,et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Darai,et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[9] A. Luini,et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. , 2009, European journal of cancer.
[10] E. Siegel,et al. Stage migration with sentinel node biopsy in breast cancer. , 2009, American journal of surgery.
[11] M. Morrow,et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Roukos,et al. Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice , 2009, Annals of Surgical Oncology.
[13] D. Evans,et al. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. , 2009, Clinical radiology.
[14] A. Soran,et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. , 2009, Journal of the American College of Surgeons.
[15] Medicina Nucleare. Is complete axillary dissection necessary for all patients with positive findings on sentinel lymph node biopsy? Validation of a breast cancer nomogram for predicting the likelihood of a non -sentinel lymph node , 2009 .
[16] J. Bevilacqua,et al. Predictive Probability of Four Different Breast Cancer Nomograms for Nonsentinel Axillary Lymph Node Metastasis in Positive Sentinel Node Biopsy , 2009 .
[17] A. Chagpar. How Many Sentinel Lymph Nodes are Enough During Sentinel Lymph Node Dissection for Breast Cancer , 2009 .
[18] I. Rubio,et al. Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[19] M. Ross,et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? , 2008, Cancer.
[20] Barbara L. Smith,et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] V. Klimberg,et al. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. , 2008, Journal of the American College of Surgeons.
[22] Barbara L. Smith,et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Brouste,et al. Distinction between isolated tumor cells and micrometastases in breast cancer , 2008, Cancer.
[24] J R Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.
[25] F. B. Sørensen,et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. McCready,et al. Sentinel Nodes in Breast Cancer: Relevance of Axillary Level II Nodes and Optimal Number of Nodes that Need to Be Removed , 2008, Annals of Surgical Oncology.
[27] G. Viale,et al. Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast: The Experience of the European Institute of Oncology on 854 Patients in 10 Years , 2008, Annals of surgery.
[28] D. Santini,et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up , 2008, Breast Cancer Research and Treatment.
[29] H. Bartelink,et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Viani,et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials , 2007, Radiation oncology.
[31] W. Woodward,et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. , 2007, International journal of radiation oncology, biology, physics.
[32] T. Julian,et al. Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS? , 2007, Annals of Surgical Oncology.
[33] J. Benson,et al. Management of the axilla in women with breast cancer. , 2007, Breast.
[34] B. Haffty. 4–50 Ipsilateral Breast Tumor Recurrence (IBTR) After Breast-Conserving Treatment for Early Breast Cancer: Risk Factors and Impact on Distant Metastases , 2007 .
[35] D. Roukos,et al. The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations , 2007, Annals of Surgical Oncology.
[36] J. Peterse,et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Bellon,et al. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. , 2006, International journal of radiation oncology, biology, physics.
[38] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[39] M. Morrow. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 , 2006 .
[40] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[41] T. Julian,et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Mitsuharu Miwa,et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer , 2005, Breast cancer.
[43] Antoine Flahault,et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement , 2005, Breast Cancer Research and Treatment.
[44] G. Hortobagyi,et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[46] Melania Pintilie,et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[47] D. Nitti,et al. Number of Metastatic Sentinel Nodes As Predictor of Axillary Involvement in Patients with Breast Cancer , 2004, Breast Cancer Research and Treatment.
[48] D. Dabbs,et al. The Optimal Number of Sentinel Lymph Nodes for Focused Pathologic Examination , 2004, The breast journal.
[49] Hiram S. Cody,et al. A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy , 2003, Annals of Surgical Oncology.
[50] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[51] Norman Wolmark,et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Anthony Fyles,et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. , 2002, Journal of the National Cancer Institute.
[53] R. Mansel,et al. Sentinel Node Biopsy in Breast Cancer: ALMANAC Trial , 2001, World Journal of Surgery.
[54] James Dignam,et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.
[55] David C. Smith,et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial , 1996, The Lancet.
[56] A P Forrest,et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. , 1996, Lancet.